- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Eyenovia, Inc.: Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension | 149 | GlobeNewswire (Europe) | Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO... ► Artikel lesen | |
| 09.04. | Eyenovia (EYEN) Down 18% on Disappointing Corporate Update | 6 | Zacks | ||
| 08.04. | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.04. | Eyenovia, Inc.: Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities | 67 | GlobeNewswire (Europe) | Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing... ► Artikel lesen | |
| 03.04. | Eyenovia, Inc.: Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings | 2 | GlobeNewswire (USA) | ||
| 19.03. | EYENOVIA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.03. | Eyenovia Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 18.03. | Recap: Eyenovia Q4 Earnings | 3 | Benzinga.com | ||
| 18.03. | Eyenovia GAAP EPS of -$0.18 misses by $0.01, revenue of $2.58M beats by $2.46M | 2 | Seeking Alpha | ||
| 18.03. | EYENOVIA, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 18.03. | Eyenovia, Inc.: Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update | 162 | GlobeNewswire (Europe) | Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to... ► Artikel lesen | |
| 13.03. | Eyenovia, Inc.: NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals | 1 | GlobeNewswire (USA) | ||
| 11.03. | Eyenovia, Inc.: Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th | 2 | GlobeNewswire (USA) | ||
| 05.03. | Eyenovia falls despite FDA nod for pain therapy | 10 | Seeking Alpha | ||
| 05.03. | After Formosa snags FDA nod for reformulation of old steroid, partner Eyenovia plots launch | 6 | FiercePharma | ||
| 05.03. | Eyenovia, Formosa Gets FDA Approval For Clobetasol Propionate Ophthalmic Eye Drops | 3 | RTTNews | ||
| 05.03. | US FDA approves Eyenovia's eye drug, Formosa Pharma says | 7 | Reuters | ||
| 29.02. | Upcoming FDA decision: Eyenovia's (EYEN) APP13007 | 5 | Seeking Alpha | ||
| 13.02. | FDA approves Eyenovia manufacturing facility in Redwood City | 4 | Seeking Alpha | ||
| 13.02. | Eyenovia passes FDA inspection for Mydcombi production | 5 | Investing.com |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,000 | +5,26 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 3,425 | +0,74 % | How Rocket Lab Outgrew Billionaire Elon Musk's Space Company in Q1 | ||
| BOIRON | 33,650 | -1,90 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| MEDICINOVA | 1,250 | 0,00 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 6,120 | -2,08 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,930 | 0,00 % | OPI, RVNC and AQST are among after hour movers | ||
| HARROW | 10,000 | 0,00 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| SHINECO | 0,799 | 0,00 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, March 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Delisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Charge Enterprises, Inc. and others from The Nasdaq Stock Market | NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of NanoString Technologies, Inc. NanoString Technologies, Inc.'s securities... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,635 | +1,55 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports Annual 2023 Financial Results | 2023 highlights include expanded FDA approval and new study publications
NASHVILLE, Tenn., March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 2,980 | -1,32 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| BAYER | 26,895 | -0,28 % | Bayer: Aktie verliert weiter - Unterstützung in Gefahr | Die Erholung bei der Bayer-Aktie Ende März war schnell wieder beendet. Zuletzt stand die Aktie erneut unter Druck. Auch am heutigen Freitagmorgen geht es weiter nach unten. Auf der Handelsplattform... ► Artikel lesen | |
| MERCK KGAA | 150,10 | -1,48 % | BARCLAYS stuft MERCK KGAA auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Merck KGaA auf "Overweight" mit einem Kursziel von 200 Euro belassen. Obwohl der Pharma- und Spezialchemiekonzern... ► Artikel lesen | |
| NOVO NORDISK | 116,20 | -1,36 % | Einmalige Chance? Die Aktien von Eli Lilly und Novo Nordisk haben noch mehr Potenzial als gedacht | Für die Pharmariesen Eli Lilly und Novo Nordisk läuft es schon länger rund. Die aktuellen Blockbuster-Medikamente könnten aber noch erfolgreicher werden als ohnehin schon. Sollten Anleger jetzt noch... ► Artikel lesen | |
| PROCESSA PHARMACEUTICALS | 2,430 | 0,00 % | Pre-market Movers: Barfresh Food, Processa Pharmaceuticals, reAlpha Tech, Biophytis, Meta Platforms | ARMONK (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Barfresh Food Group, Inc. (BRFH) is up over 96% at... ► Artikel lesen |
Das Unternehmen EYENOVIA INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,711 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
